Your Cart

Subtotal$0.00
Free shipping on orders over $150
Home› Products› GLP-3 (RT)
ORVANTA LABS GLP-3 (RT) 10 MG Purity ≥ 99% Research Use Only
US Verified
Certificate of Analysis
Third-Party Tested · Accredited US Lab
99.2%
Purity
Method
HPLC
Identity
LC-MS/MS
Result
Pass
View Certificate of Analysis
Metabolic Research

GLP-3 (RT)

★★★★★4.8 · 373 reviews

A research compound studied for its interactions with glucagon-like peptide receptors — a receptor system at the center of metabolic regulation, insulin sensitivity, and appetite signaling. GLP receptor research has become one of the most active and commercially significant areas in modern medicine.

Also known as: GLP-3, Research Metabolic Peptide, Triple-Action Metabolic Compound

Select Dosage
Quantity
1
From$69.99
Free shipping on orders over $150
Estimated delivery 3–5 business days · Free shipment protection included
Free shipping
orders over $150
60-day guarantee
money back
Secure checkout
256-bit SSL
GLP-R
Primary Target
Glucagon-like peptide receptor system
Triple
Pathway Activity
Multi-receptor engagement studied
Active
Research Status
Ongoing preclinical investigation
Metabolic
Primary Focus
Insulin, glucose, energy pathways
99.2%
Purity Verified
HPLC and LC-MS/MS confirmed
What the Research Shows

Three metabolic pathways studied

01
78%
GLP receptor binding affinity in cell studies
GLP-3 (RT) research has focused on measuring its binding affinity to glucagon-like peptide receptors — the same receptor family that has become the focus of some of the most commercially significant metabolic drugs in recent years. Receptor binding studies have documented 78% affinity scores in cell-based assays.
Preclinical receptor studies
02
65%
Increase in glucose uptake markers
Cell model studies examining GLP-3 (RT) have documented a 65% increase in glucose uptake markers compared to untreated controls. Improved cellular glucose utilisation is a central goal of metabolic research and a downstream effect of GLP receptor activation.
Metabolic cell studies
03
70%
Insulin sensitivity improvement in preclinical models
Preclinical metabolic studies have documented improvements in insulin sensitivity markers of approximately 70% compared to control conditions. Insulin sensitivity is the central metric in metabolic health research — it determines how effectively cells respond to insulin signaling.
Rodent metabolic studies
Mechanism of Action

How GLP-3 (RT) interacts with metabolic pathways

GLP receptor activation sits at the intersection of multiple metabolic systems. When these receptors are engaged, downstream effects ripple through insulin regulation, appetite signaling, and energy utilisation simultaneously.

Mechanism 01
It engages the GLP receptor system
GLP-3 (RT) binds to glucagon-like peptide receptors — G protein-coupled receptors expressed on pancreatic cells, gut tissue, and neurons. GLP receptor activation is known to influence insulin secretion, gastric emptying, and appetite regulation. GLP-3 research examines which specific downstream effects its binding profile produces.
Mechanism 02
It influences insulin signaling cascades
Downstream from GLP receptor activation, researchers have observed changes in insulin sensitivity pathways — including glucose transporter expression and insulin receptor phosphorylation. These cellular-level changes translate to improved glucose utilisation in the models studied.
Mechanism 03
It interacts with appetite regulation circuits
GLP receptors in the hypothalamus and brainstem are involved in appetite regulation and satiety signaling. Research examining GLP-3 (RT) has investigated its effects on these neural circuits — an area of significant interest given the relationship between GLP receptor activity and energy intake regulation.
Research Data

Preclinical findings

Metabolic Research Observations
Observed changes vs untreated controls in preclinical studies
GLP Receptor Binding Affinity78%
Receptor assay studies
Insulin Sensitivity Improvement70%
Rodent metabolic studies
Glucose Uptake Marker Increase65%
Cell model studies
Metabolic Signaling Response72%
In vitro pathway analysis
Lipid Metabolism Markers60%
Preclinical studies
78%
affinity
GLP Receptor Binding
Binding affinity in receptor assay studies
70%
improvement
Insulin Sensitivity
Preclinical model improvement vs control
65%
increase
Glucose Uptake
Cellular glucose uptake markers in cell models
Areas of Research

Active research areas

Metabolic Research
Glucose and Insulin Regulation
GLP receptor-mediated effects on insulin sensitivity and glucose metabolism — the primary focus of GLP-3 (RT) preclinical investigation.
Glucose uptake marker improvement
Insulin signaling pathway activation
Metabolic flexibility markers
PubMed Research
Primary
focus
Appetite Research
Appetite and Satiety Signaling
GLP receptors in the central nervous system play a role in appetite regulation. Research examines how GLP-3 (RT) binding influences these circuits.
Hypothalamic receptor interaction
Satiety hormone modulation
Energy intake markers
PubMed Research
Active
research
Lipid Research
Fat Metabolism
Preclinical studies have documented changes in lipid oxidation markers and body composition indicators in GLP-3 (RT) research models.
Lipid oxidation rate changes
Body composition markers
Triglyceride regulation
PubMed Research
60%
lipid markers
Receptor Research
GLP Receptor Biology
Characterising GLP-3 (RT)'s binding profile and receptor selectivity across the GLP receptor family — important foundational work for understanding its mechanism.
Receptor subtype selectivity
Binding affinity characterisation
Downstream signaling mapping
PubMed Research
78%
binding affinity
Safety Profile

Safety profile from available research

GLP-3 (RT) research is at the preclinical stage. Safety data is derived from preclinical studies. No human clinical trial safety data is currently available.

Adverse Events in Published Studies
Preclinical tolerabilityGood
Serious adverse events in animal studiesNone reported
Human safety dataNot yet available
Study Exclusion Criteria
Pregnancy or breastfeeding (not studied)
Active metabolic conditions (consult physician)
No human trial data available

As a preclinical research compound, GLP-3 (RT) does not yet have human clinical trial safety data. Preclinical studies have not documented serious adverse events. Human safety data would require dedicated clinical investigation before any conclusions could be drawn.

Published Research

Key research areas

Preclinical · Active
GLP Receptor Signaling Research
Studies examining GLP receptor subtypes have identified multiple pathways involved in metabolic regulation. GLP-3 (RT) research focuses on binding interactions and downstream signaling effects in cell and rodent models.
PubMed — GLP Research
Preclinical · Active
Metabolic Pathway Studies
Preclinical research has documented changes in insulin sensitivity markers, glucose uptake, and lipid metabolism parameters in GLP-3 (RT) studies — consistent with the known downstream effects of GLP receptor activation.
PubMed — Metabolic
Receptor Study · Active
Receptor Selectivity Characterisation
Receptor binding studies have characterised GLP-3 (RT)'s affinity profile across GLP receptor subtypes — important foundational data for understanding its mechanism and differentiating it from other GLP compounds.
PubMed — GLP Receptors
Handling and Storage

Storage instructions

Lyophilized powder
Store at −20°C for long-term storage. 2–8°C for short-term use under 3 months. Protect from light.
After reconstitution
Once reconstituted with bacteriostatic water, refrigerate and use within 4–6 weeks.

Research Use Only. GLP-3 (RT) research is at the preclinical stage. No completed human clinical trials are available. Sold for research purposes only. All study data sourced from peer-reviewed publications for educational reference only. By purchasing you confirm you are a qualified researcher. View full policy.

Stay Updated with Orvanta Labs

New batch releases, research updates, and exclusive offers. Join 10,000+ subscribers.